PRESS ROOM

ADAP Advocacy issued the following press releases:

---

ADAP Advocacy Publishes Infographic on 340B Drug Pricing Program

Infographic: What are Hospitals Hiding?

WASHINGTON, D.C. - (July 16, 2025) - ADAP Advocacy today, as part of its 340B Project, published a new infographic asking, "What are hospitals hiding?" The infographic complements the recently-released commercial, and is part of the ongoing 340B national advocacy campaign, "Is the 340B Drug Pricing Program the Next 'Too Big to Fail'?"

Download the Press Release:  PDF | DOC

---

ADAP Advocacy Calls for HIV Carve-Out

Centers for Medicare and Medicaid Services urged to adopt a carve-out on HIV antiretroviral therapies for the drug price negotiations under Medicare Part D, designed to protect people living with HIV/AIDS

WASHINGTON, D.C. - (July 10, 2025) - ADAP Advocacy has submitted public comments to the Centers for Medicare and Medicaid Services (CMS) regarding the proposed guidance for the Medicare Drug Price Negotiation Program (“Negotiation Program”), established under the Inflation Reduction Act (2022), calling for a carve-out on HIV antiretroviral therapies. ADAP Advocacy has requested this carve-out exemption due to the serious nature of the threat facing People Living with HIV/AIDS (PLWHA), should HIV medications be selected as part of the Negotiation Program.

Download the Press Release:  PDF | DOC

---

ADAP Advocacy Applauds Texas HIV Advocates

Texas Legislature approves $338 billion two-year spending plan with funds to support Long-Acting Injectables (LAIs) for the Texas AIDS Drug Assistance Program

WASHINGTON, D.C. - (June 26, 2025) - ADAP Advocacy today applauded HIV advocates in the Lone Star State for their tireless advocacy in helping to add long-acting injectables (LAIs) to the Texas HIV Medication Program’s (THMP) drug formulary, along with $600,000 allocated to fund it. The two-year budget included $300,000 for fiscal year 2026 and $300,000 for fiscal year 2027, as well as some additional funding. Texas had been one of the remaining four states without Cabenuva (cabotegravir/rilpivirine) covered under its drug formularies.

Download the Press Release:  PDF | DOC

---

ADAP Advocacy Publishes Infographic on 340B Drug Pricing Program

Infographic: Is the 340B Drug Pricing Program the Next 'Too Big to Fail'?

WASHINGTON, D.C. - (June 10, 2025) - ADAP Advocacy today, as part of its 340B Project, published a new infographic highlighting similarities between the 2008 financial crisis and the current healthcare crisis. The infographic complements the recently-released commercial, and is part of the ongoing 340B national advocacy campaign, "Is the 340B Drug Pricing Program the Next 'Too Big to Fail'?"

Download the Press Release:  PDF | DOC

---

ADAP Advocacy Applauds U.S. Sen. Bill Cassidy’s Report on 340B Reform

Congressional Action Needed to Strengthen the Program with Long-Overdue Accountability and Transparency Standards to Combat Waste, Fraud & Abuse

WASHINGTON, D.C. - (April 25, 2025) - ADAP Advocacy applauded U.S. Senator Bill Cassidy for his leadership on reforming the 340B Drug Pricing Program, notably the release of his comprehensive report outlining the potential reforms needed to improve the program and better serve patients. The report’s findings are broadly consistent with what has been supported by ADAP Advocacy’s 340B Patient Advisory Committee over the last two years.

Download the Press Release:  PDF | DOC

---

ADAP Advocacy Releases Report on Patient Medical Debt

Findings from Quantitative Surveying of Patients in the United States

WASHINGTON, D.C. - (April 23, 2025) - ADAP Advocacy today, as part of its 340B Project and in collaboration with the Community Access National Network (CANN), published a report on patient experiences with and perspectives on medical debt. The report – “Patient Medical Debt: Findings from Quantitative Surveying of Patients in the United States – April 2025” – found that nearly four out of five patients delayed or avoided medical care due to inability to pay (excluding the purchase of prescription drugs), and three-fourths of patients held medical debt.

Download the Press Release:  PDF | DOC

---

ADAP Advocacy Releases 2024 Annual Report

Advocacy Agenda Largely Focused on HIV Long-Acting Injectables and the 340B Drug Pricing Program

WASHINGTON, D.C. - (April 14, 2025) - ADAP Advocacy released its 2024 Annual Report today, highlighting the organization’s ongoing commitment to access, information, and participation in patient advocacy designed to promote and protect the AIDS Drug Assistance Program (“ADAP”). The report is shared using an infographic format to capture the previous year’s highlights.

Download the Press Release:  PDF | DOC

---

ADAP Advocacy Announces Health Fireside Chat – Minneapolis, MN

Two-day policy retreat entirely dedicated to the Inflation Reduction Act and its emerging adverse impact on patient access to care and treatment

WASHINGTON, D.C. - (April 8, 2025) - ADAP Advocacy today announced its 2025 Health Fireside Chat in Minneapolis, Minnesota, which will be held June 13th-14th.

Download the Press Release:  PDF | DOC

---

ADAP Advocacy & CANN Joint Statement On Reported HIV Prevention Funding Cuts

Critical HIV Prevention Programs Facing Potential Elimination

WASHINGTON, D.C. - (March 19, 2025) - The ADAP Advocacy Association and the Community Access National Network (CANN) express deep concern regarding a recent Wall Street Journal report that the U.S. Department of Health and Human Services is considering significant cuts to domestic HIV prevention funding. According to the report, programs potentially facing reduction or elimination include the Centers for Disease Control and Prevention (CDC)’s PrEP initiative and other prevention efforts, potentially impacting the entire $1.3 billion CDC HIV Prevention Program.

Download the Press Release:  PDF | DOC

---

ADAP Advocacy Releases New Policy Paper on 340B Drug Pricing Program

Is the 340B Drug Pricing Program the Next 'Too Big to Fail'?

WASHINGTON, D.C. - (March 12, 2025) - ADAP Advocacy today, as part of its 340B Project, published a new policy paper on the 340B Drug Pricing Program. The report – “Is the 340B Drug Pricing Program the Next ‘Too Big to Fail’?” – sounds the alarm on why common sense reforms are needed to ensure the integrity of the nation’s second largest federally sponsored drug program, behind only Medicare Part D. The policy paper compares the 340B Program’s lack of meaningful accountability or transparency standards, especially among the big hospital systems, despite explosive growth to the collapse of the financial markets in 2007-08 after years of minimal federal oversight of the big investment banks.

Download the Press Release:  PDF | DOC

---

ADAP Advocacy Releases Supplemental Report on 340B Covered Entities

The 340B Drug Pricing Program and Its Potential Impacts on Annual Revenues, Executive Compensation, and Charity Care Provision in Eligible Covered Entities

WASHINGTON, D.C. - (March 4, 2025) - ADAP Advocacy today, as part of its 340B Project and in collaboration with the Community Access National Network (CANN), published a supplemental report on the 340B Drug Pricing Program and its impact on covered entities’ executive compensation. The report - "The 340B Drug Pricing Program and its Potential Impacts on Annual Revenues, Executive Compensation, and Charity Care Provision in Eligible Covered Entities–Supplemental Report" - found that among the 33 covered entities audited their annual revenues increased by an average of 772.92%, while executive compensation increased by an average of 237.11%.

Download the Press Release:  PDF | DOC

---

ADAP Advocacy Files Amicus Curiae Briefs Supporting 340B Rebate Model

Two amicus briefs offer distinctly patient-focused perspective on the importance of the rebate model to patients and why that model is so desperately needed

WASHINGTON, D.C. - (February 11, 2025) - ADAP Advocacy today announced it has filed two amicus curiae briefs in support drug manufacturers motion for summary judgement against the Health Resources Services Administration, arguing the program is failing patients. Both briefs, which were filed jointly with CF United, outline how the program has grown, the level of chief executive compensation (which often has increased, quite dramatically), and the level of charity care (which fails, rather consistently, to correspond in any meaningful way to the explosive program expansion).

Download the Press Release:  PDF | DOC

---

ADAP Advocacy Names William Sarraille as Special Counsel for 340B Issues

Sarraille is a nationally recognized expert in health care, life sciences, drugs, medical devices, and patient access to treatments

WASHINGTON, D.C. - (February 6, 2025) - ADAP Advocacy today announced that William "Bill" Sarraille will serve as Special Counsel on issues related to the 340B Drug Pricing Program. Sarraille will advise the organization, and its 340B Patient Advisory Committee, on 340B public policy, federal and state legislative and regulatory matters, and efforts to reform the program to better serve patients.

Download the Press Release:  PDF | DOC

---

ADAP Advocacy Warns Advocates Potential HIV Funding Cuts Loom

Funding for Ryan White HIV/AIDS Program-related programs potentially on the budgetary chopping block as part of the ongoing attacks on gender-affirming health and reproductive health

WASHINGTON, D.C. - (January 30, 2025) - ADAP Advocacy today issued a stark warning to patients, patient advocates, and public policy stakeholders in anticipation of looming budget cuts to HIV-related programs. Grassroots networks are encouraged to prepare themselves to engage with lawmakers and their staff.

Download the Press Release:  PDF | DOC

---

Past Press Releases:
[2024] · [2023] · [2022] · [2021] · [2020] · [2019] · [2018] · [2017] · [2016] · [2015] · [2014] · [2013] · [2012] · [2011] · [2010] · [2009]